Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec

Eskazan, Ahmet; Sadri, Sevil; Keskin, Dilek; Ayer, Mesut; Kantarcioglu, Bulent; Demirel, Naciye; Aydin, Demet; Aydinli, Fuat; Yokus, Osman; Ozunal, Isil; Berk, Selin; Yalniz, Fevzi; Elverdi, Tugrul; Salihoglu, Ayse; Ar, Muhlis; Ongoren, Seniz; Baslar, Zafer; Aydin, Yildiz; Tuzuner, Nukhet; ÖZBEK, UĞUR; Soysal, Teoman

doi:10.1016/j.clml.2017.07.255

Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec

Atıf İçin Kopyala

Eskazan A. E., Sadri S., Keskin D., Ayer M., Kantarcioglu B., Demirel N., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.17, sa.12, ss.804-811, 2017 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 17 Sayı: 12
Basım Tarihi: 2017
Doi Numarası: 10.1016/j.clml.2017.07.255
Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.804-811
Anahtar Kelimeler: BCR-ABL1, CML, Generic imatinib, Outcome, Response, CHRONIC PHASE, MANAGEMENT, MESYLATE, CML
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

We retrospectively evaluated 90 patients with chronic myeloid leukemia receiving either upfront original imatinib (Ol) or generic imatinib (Gl) for the effect of the early molecular response on the long-term outcome. We demonstrated that achieving an optimal response at 3 and 6 months in patients receiving either first-line Gl or Ol was clearly associated with greater response and event-free survival rates.